{"altmetric_id":216558,"counts":{"readers":{"mendeley":14,"citeulike":0,"connotea":1},"facebook":{"unique_users_count":1,"unique_users":["351778649052"],"posts_count":1},"total":{"posts_count":1}},"citation":{"altmetric_jid":"4f6fa4e93cf058f61000245c","authors":["Neil Scolding"],"doi":"10.1136\/bmj.c2882","first_seen_on":"2011-08-11T00:09:22+00:00","issns":["1468-5833"],"journal":"British Medical Journal","last_mentioned_on":1276027898,"links":["http:\/\/www.bmj.com\/cgi\/content\/full\/340\/jun03_1\/c2882?maxtoshow&hits=10&RESULTFORMAT&fulltext=interferons+MS&searchid=1&FIRSTINDEX=0&sortspec=date&resourcetype=HWCIT"],"pmid":"20522661","pubdate":"2010-01-01T00:00:00+00:00","publisher":"British Medical Journal Publishing Group","publisher_subjects":[{"name":"Public Health And Health Services","scheme":"era"}],"scopus_subjects":["Medicine","Health Sciences"],"subjects":["medicine"],"title":"The multiple sclerosis risk sharing scheme","type":"article","volume":"340","mendeley_url":"http:\/\/www.mendeley.com\/research\/multiple-sclerosis-risk-sharing-scheme-6"},"altmetric_score":{"score":0.25,"score_history":{"1y":0,"6m":0,"3m":0,"1m":0,"1w":0,"6d":0,"5d":0,"4d":0,"3d":0,"2d":0,"1d":0,"at":0.25},"context_for_score":{"all":{"total_number_of_other_articles":5269182,"mean":6.2011712245248,"rank":4386846,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":5269182,"percentile":1},"similar_age_3m":{"total_number_of_other_articles":61929,"mean":5.5255856478491,"rank":52875,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":61929,"percentile":1},"this_journal":{"total_number_of_other_articles":26781,"mean":21.010994846901,"rank":25475,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":26781,"percentile":1},"similar_age_this_journal_3m":{"total_number_of_other_articles":646,"mean":9.096511627907,"rank":582,"this_scored_higher_than_pct":1,"this_scored_higher_than":0,"rank_type":"exact","sample_size":646,"percentile":1}}},"demographics":{"users":{"mendeley":{"by_status":{"Researcher":4,"Student  > Ph. D. Student":2,"Student  > Postgraduate":1,"Student  > Master":4,"Student  > Bachelor":1,"Professor":2},"by_discipline":{"Engineering":1,"Medicine and Dentistry":6,"Social Sciences":3,"Economics, Econometrics and Finance":2,"Agricultural and Biological Sciences":1,"Business, Management and Accounting":1}}}},"posts":{"facebook":[{"title":"www.bmj.com","url":"https:\/\/www.facebook.com\/permalink.php?story_fbid=130609433631748&id=351778649052","citation_ids":[216558],"posted_on":"2010-06-08T20:11:38+00:00","summary":"Should we be prescribing interferons for MS after MS risk-sharing scheme data?  Editorial from Professor Neil Scolding.\nhttp:\/\/www.bmj.com\/cgi\/content\/full\/340\/jun03_1\/c2882?maxtoshow=&hits=10&RESULTFORMAT=&fulltext=interferons+MS&searchid=1&FIRSTINDEX=0&s","author":{"name":"IWGYNT","url":"https:\/\/www.facebook.com\/351778649052","facebook_wall_name":"IWGYNT","image":"https:\/\/graph.facebook.com\/351778649052\/picture","id_on_source":"351778649052"}}]}}